MedTrace Logo

Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

NCT05419102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2022-06-15

No results posted yet for this study

Summary

The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.

Conditions

  • Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment

Interventions

PROCEDURE

peri-implantitis surgery with enamel matrix derivative

surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.

Sponsors & Collaborators

  • North Dallas Dental Health

    lead OTHER

Principal Investigators

  • Thomas G Wilson

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-05-15
Completion
2022-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05419102 on ClinicalTrials.gov